KRAS and pancreatic neoplasm: Enlarging the search for KRAS mutations to other screened codons increased the sensitivity to 20.9% (83 patients with pancreatic cancer carrying at least one mutations in their cfDNA), but decreased the specificity with the detection of cfDNA KRAS mutations in 6/132 (4.5%) patients with chronic pancreatitis and in 14/374 (3.7%) healthy controls (Table 4).